Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Pronorvista on Aug 05, 2021 10:52pm

ATE

Filing
DateTransaction
DateInsider NameOwnership
TypeSecuritiesNature of transactionVolume or ValuePriceAug 5/21Aug 5/21Stauffer, JosephDirect OwnershipCommon Shares10 - Acquisition in the public market17,343$0.857
USDAug 5/21Aug 5/21Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market3,000$1.08
Aug 5/21Aug 5/21Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market7,000$1.06
Aug 5/21Aug 4/21Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market12,500$1.02
Aug 5/21Aug 4/21Wallace, John LawrenceDirect OwnershipCommon Shares10 - Acquisition in the public market10,300$1.04
Jul 15/21Jul 14/21Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market2,600$3.42
Jul 15/21Jul 13/21Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market4,000$3.57
Jul 4/21Jun 30/21Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market3,500$3.71
Jul 4/21Jun 30/21Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market4,000$3.70
Jun 6/21Jun 3/21Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Disposition in the public market-75,000$4.00
Comment by CalmBeforeStorm on Aug 05, 2021 11:12pm
To me, that level of insider buying is window dressing for us retail investors. Sorry, at these levels, I'm not buying it!  Still holding...I share your pain.  
Comment by Pandora on Aug 06, 2021 1:44am
As of 11:59pm ET August 5th, 2021 Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction Volume or Value Price Aug 5/21 Aug 5/21 Stauffer, Joseph Direct Ownership Common Shares 10 - Acquisition in the public market 17 ...more  
Comment by rixpix on Aug 06, 2021 8:54am
The purchases are not really that convincing. I was expecting a lot more shares to be bought. Pretty much symbolic if not anything else. Marcel sold 75K @ 4 buxx and only buys 12K now?  Not too re-assuring....
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities